Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $22.94 in the prior trading day, Celldex Therapeutics Inc (NASDAQ: CLDX) closed at $22.62, down -1.39%. In other words, the price has decreased by -$1.39 from its previous closing price. On the day, 1.28 million shares were traded. CLDX stock price reached its highest trading level at $23.87 during the session, while it also had its lowest trading level at $22.47.
Ratios:
Our goal is to gain a better understanding of CLDX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 24.27 and its Current Ratio is at 24.27. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on October 07, 2024, initiated with a Buy rating and assigned the stock a target price of $70.
On September 30, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $45.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 11 ’24 when Marucci Anthony S bought 11,500 shares for $26.82 per share. The transaction valued at 308,430 led to the insider holds 40,284 shares of the business.
Martin Samuel Bates sold 17,172 shares of CLDX for $608,315 on Jun 14 ’24. The SVP AND CFO now owns 28,125 shares after completing the transaction at $35.42 per share. On Jun 14 ’24, another insider, Crowley Elizabeth, who serves as the SR. VP & CPDO of the company, sold 30,000 shares for $34.87 each. As a result, the insider received 1,045,962 and left with 9,074 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 1500705920 and an Enterprise Value of 747794624. For the stock, the TTM Price-to-Sale (P/S) ratio is 150.37 while its Price-to-Book (P/B) ratio in mrq is 1.91. Its current Enterprise Value per Revenue stands at 74.959 whereas that against EBITDA is -4.372.
Stock Price History:
The Beta on a monthly basis for CLDX is 1.63, which has changed by -0.42158347 over the last 52 weeks, in comparison to a change of 0.22212577 over the same period for the S&P500. Over the past 52 weeks, CLDX has reached a high of $53.18, while it has fallen to a 52-week low of $22.88. The 50-Day Moving Average of the stock is -12.69%, while the 200-Day Moving Average is calculated to be -33.29%.
Shares Statistics:
The stock has traded on average 1.05M shares per day over the past 3-months and 1205220 shares per day over the last 10 days, according to various share statistics. A total of 66.34M shares are outstanding, with a floating share count of 64.70M. Insiders hold about 2.48% of the company’s shares, while institutions hold 107.02% stake in the company. Shares short for CLDX as of 1735603200 were 8086627 with a Short Ratio of 7.71, compared to 1732838400 on 7701959. Therefore, it implies a Short% of Shares Outstanding of 8086627 and a Short% of Float of 14.099999999999998.
Earnings Estimates
The performance of Celldex Therapeutics Inc (CLDX) in the stock market is under the watchful eye of 8.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.85, with high estimates of -$0.79 and low estimates of -$0.91.
Analysts are recommending an EPS of between -$2.15 and -$2.62 for the fiscal current year, implying an average EPS of -$2.4. EPS for the following year is -$3.33, with 7.0 analysts recommending between -$2.99 and -$3.66.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for CLDX’s current fiscal year. The highest revenue estimate was $9.3M, while the lowest revenue estimate was $5.8M, resulting in an average revenue estimate of $6.83M. In the same quarter a year ago, actual revenue was $6.88M
